Correlation Between Elevation Oncology and Lexicon Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Elevation Oncology and Lexicon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Elevation Oncology and Lexicon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Elevation Oncology and Lexicon Pharmaceuticals, you can compare the effects of market volatilities on Elevation Oncology and Lexicon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Elevation Oncology with a short position of Lexicon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Elevation Oncology and Lexicon Pharmaceuticals.

Diversification Opportunities for Elevation Oncology and Lexicon Pharmaceuticals

0.76

Correlation Coefficient

Elevation Oncology  Lexicon Pharmaceuticals

Poor diversification

The 3 months correlation between Elevation and Lexicon is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Elevation Oncology and Lexicon Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lexicon Pharmaceuticals and Elevation Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Elevation Oncology are associated (or correlated) with Lexicon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lexicon Pharmaceuticals has no effect on the direction of Elevation Oncology i.e., Elevation Oncology and Lexicon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Elevation Oncology and Lexicon Pharmaceuticals

Given the investment horizon of 90 days Elevation Oncology is expected to under-perform the Lexicon Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Elevation Oncology is 1.52 times less risky than Lexicon Pharmaceuticals. The stock trades about -0.11 of its potential returns per unit of risk. The Lexicon Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  72.00  in Lexicon Pharmaceuticals on December 30, 2024 and sell it today you would lose (15.00) from holding Lexicon Pharmaceuticals or give up 20.83% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Elevation Oncology  vs.  Lexicon Pharmaceuticals

Elevation Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Elevation Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Lexicon Pharmaceuticals

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Lexicon Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Lexicon Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Elevation Oncology and Lexicon Pharmaceuticals

The main advantage of trading using opposite Elevation Oncology and Lexicon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Elevation Oncology position performs unexpectedly, Lexicon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexicon Pharmaceuticals will offset losses from the drop in Lexicon Pharmaceuticals' long position.

The idea behind Elevation Oncology and Lexicon Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.